New monoclonal antibody vaccine slashes malaria risk in children

A recent study demonstrates that the monoclonal antibody-based vaccine L9LS is safe for children aged 6 to 10 and significantly reduces the risk of malaria infection and clinical symptoms by 70% and 77%, respectively.

Related Keywords

Toronto ,Ontario ,Canada ,Mali ,China ,Chinese ,Malian ,Kateryna Kon ,Subcutaneous Administration ,International Council For Harmonisation Good Clinical Practises ,Drug Administration ,National Institute Of Allergy ,World Health Organization ,New England Journal ,Monoclonal Antibody ,Image Credit ,International Council ,Good Clinical Practises ,Malian Food ,National Institute ,Antibody ,Children ,Malaria ,Vaccine ,Flood ,Fell ,Efficacy ,Medicine ,Mosquito ,Placebo ,Plasmodium Falciparum ,